Stock 6838 FORMOSA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Formosa Pharmaceuticals, Inc.

Equities

6838

TW0006838006

End-of-day quote Taipei Exchange
Other stock markets
 03:30:00 16/07/2024 am IST 		5-day change 1st Jan Change
55.1 TWD 0.00% Intraday chart for Formosa Pharmaceuticals, Inc. +1.10% +10.31%
09/05 Formosa Pharmaceuticals Announces Licensing Agreement with Tabuk Pharmaceuticals, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery CI
07/03 Formosa Pharmaceuticals, Inc. Announces FDA Approval for the NDA of A Global Innovative Hormone Nanosuspension Eye Drops CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Formosa Pharmaceuticals Announces Licensing Agreement with Tabuk Pharmaceuticals, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
Formosa Pharmaceuticals, Inc. Announces FDA Approval for the NDA of A Global Innovative Hormone Nanosuspension Eye Drops
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery
US FDA approves Eyenovia's eye drug, Formosa Pharma says
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Formosa Pharmaceuticals Announces Licensing Agreement with Cristália, for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular Surgery
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
Formosa Pharmaceuticals and AimMax Therapeutics Announce the NDA Submission to the US FDA for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery
Grand Pharmaceutical Group's Eye Drops Show Safety in Phase 2, 3 Trials
Formosa Pharmaceuticals, Inc. Announces Phase III Clinical Study of a Global Innovative Hormone Nanosuspension Eye Drops Successfully Reached Clinical Endpoint
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Formosa Pharmaceuticals, Inc. Enter into A Collaboration Agreement with Eyenovia, Inc. for the Development of Novel Ophthalmic Therapeutics
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022
Formosa Pharmaceuticals, Inc. and AimMax Therapeutics, Inc. Announce Successful Top-Line Results from CPN-302 for the Treatment of Inflammation and Pain after Cataract Surgery
Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-301 for the Treatment of Inflammation and Pain after Cataract Surgery
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
HCmed Innovations, Formosa Laboratories, and Formosa Pharmaceuticals Signs MoU to Form A Global CDMO for Inhalation Treatment Drugs
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 6838 Stock
  4. News Formosa Pharmaceuticals, Inc.
  5. Other languages